Jagsonpal Pharma Buyback: ₹40 Crore Plan Lifts Stock 12%

Introduction

Shares of Jagsonpal Pharmaceuticals surged over 12% on Thursday, March 12, 2026, after the company's board of directors approved a proposal to buy back equity shares. The plan involves repurchasing up to 16 lakh shares at a price of ₹250 each, aggregating to a total outlay of ₹40 crore. This strategic move is aimed at returning surplus cash to shareholders and reflects management's confidence in the company's valuation.

Details of the Buyback Offer

The board has approved the buyback of up to 1,600,000 equity shares, which represents 2.39% of the company's total paid-up equity capital. The buyback will be conducted via the tender offer route. The offer price of ₹250 per share marks a significant premium of 39.74% over the previous day's closing price of ₹178.90 on the BSE. The total buyback size of ₹40 crore represents 18.35% of the company's paid-up equity share capital and free reserves as of March 31, 2025.

Immediate Market Reaction

The announcement was met with strong investor enthusiasm. The stock price of Jagsonpal Pharmaceuticals jumped 12.4% to hit an intraday high of ₹201.50 per share. By mid-afternoon, the stock was trading at ₹195.60, up 9.33% from its previous close, indicating a robust positive response from the market to the capital return strategy.

Strategic Rationale and Objectives

A share buyback is often seen as a tax-efficient way to reward shareholders. By reducing the number of outstanding shares, the company aims to improve key financial metrics such as Earnings Per Share (EPS) and Return on Equity (ROE). This can make the remaining shares more valuable to investors. The company stated that the primary objective of the buyback is to return surplus cash to its shareholders, signaling that the management believes the stock may be undervalued at its current market price.

Impact on Shareholding Pattern

A key aspect of this buyback is its effect on the company's ownership structure. The promoter and promoter group, who currently hold 67.2% of the company, will not participate in the tender offer. Assuming the buyback is fully subscribed, their shareholding is expected to increase to 68.9%. Consequently, the public shareholding will decrease from the current 32.8% to approximately 31.1%. This move effectively increases the stake of the promoters without any additional investment.

Company's Financial Health

Jagsonpal Pharmaceuticals has demonstrated a solid financial position, making it capable of executing this buyback. The company operates with a zero debt-to-equity ratio, indicating a strong balance sheet. For the fiscal year ending March 2025, the company reported sales of ₹268 crore and a net profit of ₹55 crore, a significant increase from the previous year. However, for the third quarter of FY26 (ending December 2025), the company saw a slight dip, with a standalone net profit of ₹12.49 crore on net sales of ₹72.95 crore. The buyback is funded from the company's cash reserves.

Governance and Next Steps

To manage the process, Jagsonpal Pharmaceuticals has appointed Centrum Capital Limited as the Manager to the Buyback. The board has also constituted a "Buyback Committee" to oversee the process, including fixing the record date for determining shareholder eligibility. The buyback proposal is now subject to approval from the shareholders, which will be sought through a postal ballot. The company will announce the record date and other timelines for the tender offer in due course.

About Jagsonpal Pharmaceuticals

Founded as a pharmaceutical company, Jagsonpal has a diversified portfolio of drugs with a focus on key therapeutic areas such as gynaecology, orthopaedics, dermatology, and child-care. The company is engaged in the manufacturing and trading of both pharmaceutical products and active pharmaceutical ingredients (APIs). Its established presence in these segments provides a stable revenue stream.

Conclusion

The ₹40 crore share buyback by Jagsonpal Pharmaceuticals is a significant corporate action that underscores the management's commitment to enhancing shareholder value. The attractive premium and the resulting improvement in financial ratios have been well-received by the market. Investors will now await further announcements regarding the record date and the schedule for the tender offer process.